The burden of adverse drug events

被引：9

作者：

Breckenridge, Alasdair ^{[1
]}

机构：

[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2015年 / 80卷 / 04期

关键词：

benefit risk balance; drug safety;

D O I：

10.1111/bcp.12507

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Drug safety should be considered as part of the balance between benefit and risk, and represents a burden to the patient, the healthcare professional, the regulator and industry. Each of these has a different view on adverse drug reactions and these are discussed in this article.

引用

页码：785 / 787

页数：3

共 6 条

[1]

[Anonymous], 2012, ETH SCI ISS STUD SAF

[2]

Institute of Medicine, 2007, FUT DRUG SAF PROM PR

[3] Incidence of adverse drug reactions in hospitalized patients - A meta-analysis of prospective studies [J].

Lazarou, J ;

Pomeranz, BH ;

Corey, PN .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (15) :1200-1205

[4] Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (vol 356, pg 2457, 2007) [J].

Nissen, Steven E. ;

Wolski, Kathy .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24) :2457-2471

[5] Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients [J].

Pirmohamed, M ;

James, S ;

Meakin, S ;

Green, C ;

Scott, AK ;

Walley, TJ ;

Farrar, K ;

Park, BK ;

Breckenridge, AM .

BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7456) :15-19

[6] New approaches to drug safety: a pharmacovigilance tool kit [J].

Wise, Lesley ;

Parkinson, John ;

Raine, June ;

Breckenridge, Alasdair .

NATURE REVIEWS DRUG DISCOVERY, 2009, 8 (10) :779-782

← 1 →